Corbus Pharmaceuticals Holdings Inc (CRBP.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Corbus Pharmaceuticals Receives $25 Mln Development Award From The Cystic Fibrosis Foundation
- BRIEF-Corbus Agrees With FDA On Phase 2B Cystic Fibrosis Study Design With Pulmonary Exacerbations As Sole Primary Endpoint
- Corbus cystic fibrosis drug to get FDA review on flare-up data
- Corbus cystic fibrosis drug to get U.S. FDA review on flare-up data
- BRIEF-Corbus Pharmaceuticals Files For Mixed Shelf Of Up To $200 Mln